Test Predicts Which CRC Patients Benefit from Adjuvant Chemo

Testing for molecular residual disease was able to identify patients with early-stage colorectal cancer who are most likely to benefit from adjuvant chemotherapy.
Medscape Medical News

source https://www.medscape.com/viewarticle/986992?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost